PFAS (per- and polyfluoroalkyl substances) reach developing fetuses through the placenta, and the evidence linking prenatal PFAS exposure to adverse pregnancy outcomes has strengthened substantially over the past fifteen years. This article reviews what the peer-reviewed research has established: placental transfer, associations with birth weight, links to preeclampsia, and the interventions with the clearest evidence for reducing exposure before and during pregnancy.
Placental transfer is real and well characterised
Multiple cohort studies have measured PFAS concentrations in paired maternal and cord blood samples. A 2014 paper published in Environmental Science and Technology analysed mother-infant pairs and found that all major PFAS compounds (PFOA, PFOS, PFNA, PFHxS) were detected in cord blood, with transfer ratios ranging from approximately 0.3 for PFOS to 0.8 for PFOA. A subsequent review in Environmental Research aggregated findings from more than twenty studies and confirmed consistent placental transfer across populations in North America, Europe and Asia.
Shorter-chain PFAS (such as PFBA and PFBS) cross the placenta even more readily than the legacy long-chain compounds they were introduced to replace. This matters because the industry responded to regulation of PFOA and PFOS by substituting shorter-chain variants marketed as safer; the placental transfer data suggest this framing was incomplete.
Birth weight associations
The C8 Health Project, a large community study of residents near a DuPont plant in the Mid-Ohio Valley with historically elevated drinking water PFOA, produced some of the strongest human evidence. Analyses of the C8 cohort, published across multiple papers in the early 2010s, found inverse associations between maternal PFOA serum concentrations and infant birth weight, with each doubling of PFOA exposure associated with approximately 10 to 20 grams lower birth weight.
The Faroe Islands birth cohorts, led by Philippe Grandjean, extended the evidence. A 2020 paper in Environmental Health Perspectives analysing the Faroese data reported that prenatal PFAS exposure was associated with reduced birth weight and with altered immune function in childhood, including reduced antibody response to routine vaccinations. A 2022 meta-analysis in JAMA Pediatrics pooling results from 24 studies found a consistent, small but statistically significant inverse association between maternal PFOA exposure and birth weight. The effect size at typical population exposures is modest, but because birth weight is population-distributed, small shifts at the mean translate to meaningful increases at the low-birth-weight tail.
Preeclampsia and gestational hypertension
Several prospective studies have reported associations between maternal PFAS concentrations and preeclampsia or pregnancy-induced hypertension. The C8 Health Project analyses found that women with the highest quartile of PFOA serum concentrations had approximately 30% higher odds of pregnancy-induced hypertension compared with the lowest quartile. A 2014 paper in the American Journal of Epidemiology confirmed this association in the full C8 cohort.
The biological plausibility includes effects on endothelial function, lipid metabolism and the renin-angiotensin system. PFAS have been shown to increase circulating cholesterol and to alter vascular reactivity in both animal and human studies. Preeclampsia is a multifactorial condition, and PFAS are one of several modifiable contributors alongside blood pressure management, weight and nutrition.
Mechanisms that matter in pregnancy
PFAS act through several pathways with particular relevance to pregnancy. They are known peroxisome proliferator-activated receptor (PPAR) agonists, which affects lipid and glucose metabolism in both mother and fetus. They disrupt thyroid hormone signalling: research in the Journal of Clinical Endocrinology and Metabolism found that higher maternal PFAS was associated with subclinical hypothyroidism, and fetal brain development is highly dependent on maternal thyroid hormone in the first trimester.
PFAS also concentrate in breast milk. A 2022 study in Environmental Science and Technology found that serum PFAS levels decrease during lactation, implying transfer to the infant. The practical implication is not to stop breastfeeding (whose benefits substantially outweigh PFAS exposure in virtually all modelled scenarios) but to reduce body burden before pregnancy so the available reservoir is smaller.
What to reduce first
Given that PFOA has a serum half-life of roughly 3.8 years in adults, exposure reduction ideally begins well before conception rather than at the positive pregnancy test. Three interventions have the best evidence-to-effort ratio. First, test or filter drinking water; in areas with known PFAS contamination, water can contribute 20 to 40% of total PFAS body burden, and a reverse osmosis filter or certified NSF/ANSI 53 and 58 system removes the covered compounds. Second, replace non-stick cookware, because PTFE coatings degrade above 260 C and release PFAS. Cast iron, carbon steel and stainless steel are all validated alternatives. Third, reduce contact with fluorinated food packaging: fast food wrappers, microwave popcorn bags and grease-resistant takeout containers are among the most heavily PFAS-coated food contact materials.
The evidence is not that PFAS cause pregnancy complications in any individual case, but that population-level PFAS exposure shifts outcomes at the margin across birth weight, preeclampsia risk and childhood immune function. Exposure reduction before pregnancy is one of the few actions supported by consistent cohort data across multiple continents.